Stoke Therapeutics Comes Out of Seed Mode With $40M and Ex-Sarepta CEO at Its Helm Post author:Sam Post published:January 3, 2018 Post category:BioPharma The Series A round was entirely funded by founding investor Apple Tree Partners. Source: BioSpace You Might Also Like Incoming Novartis CEO, Bayer Leader Join President Trump for Private Dinner at Davos January 25, 2018 This Massachusetts Marijuana Biotech is Betting the Farm on One Single Drug October 24, 2017 Why AbbVie Could Join the M&A Mania Soon January 30, 2018
Incoming Novartis CEO, Bayer Leader Join President Trump for Private Dinner at Davos January 25, 2018
